These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1129 related items for PubMed ID: 17511819

  • 1. Predictors for persistent cytomegalovirus reactivation after T-cell-depleted allogeneic hematopoietic stem cell transplantation.
    Almyroudis NG, Jakubowski A, Jaffe D, Sepkowitz K, Pamer E, O'Reilly RJ, Papanicolaou GA.
    Transpl Infect Dis; 2007 Dec; 9(4):286-94. PubMed ID: 17511819
    [Abstract] [Full Text] [Related]

  • 2. Pre-transplant cytomegalovirus (CMV) serostatus remains the most important determinant of CMV reactivation after allogeneic hematopoietic stem cell transplantation in the era of surveillance and preemptive therapy.
    George B, Pati N, Gilroy N, Ratnamohan M, Huang G, Kerridge I, Hertzberg M, Gottlieb D, Bradstock K.
    Transpl Infect Dis; 2010 Aug 01; 12(4):322-9. PubMed ID: 20487414
    [Abstract] [Full Text] [Related]

  • 3. Cytomegalovirus infection in children who underwent hematopoietic stem cell transplantation at a single center: a retrospective study of the risk factors.
    Yoon HS, Lee JH, Choi ES, Seo JJ, Moon HN, Kim MN, Im HJ.
    Pediatr Transplant; 2009 Nov 01; 13(7):898-905. PubMed ID: 19032414
    [Abstract] [Full Text] [Related]

  • 4. Interferon gamma 13-CA-repeat homozygous genotype and a low proportion of CD4(+) lymphocytes are independent risk factors for cytomegalovirus reactivation with a high number of copies in hematopoietic stem cell transplantation recipients.
    Jaskula E, Dlubek D, Duda D, Bogunia-Kubik K, Mlynarczewska A, Lange A.
    Biol Blood Marrow Transplant; 2009 Oct 01; 15(10):1296-305. PubMed ID: 19747638
    [Abstract] [Full Text] [Related]

  • 5. Persisting posttransplantation cytomegalovirus antigenemia correlates with poor lymphocyte proliferation to cytomegalovirus antigen and predicts for increased late relapse and treatment failure.
    Nakamura R, Battiwalla M, Solomon S, Follmann D, Chakrabarti S, Cortez K, Hensel N, Childs R, Barrett AJ.
    Biol Blood Marrow Transplant; 2004 Jan 01; 10(1):49-57. PubMed ID: 14752779
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Kinetics of interferon-gamma producing cytomegalovirus (CMV)-specific CD4+ and CD8+ T lymphocytes and the risk of subsequent CMV viremia after allogeneic hematopoietic stem cell transplantation.
    Eid AJ, Brown RA, Hogan WJ, Lahr BD, Eckel-Passow JE, Litzow MR, Razonable RR.
    Transpl Infect Dis; 2009 Dec 01; 11(6):519-28. PubMed ID: 19744286
    [Abstract] [Full Text] [Related]

  • 8. High-dose acyclovir and pre-emptive ganciclovir in prevention of cytomegalovirus disease in pediatric patients following peripheral blood stem cell transplantation.
    Hazar V, Kansoy S, Küpesiz A, Aksoylar S, Kantar M, Yeşilipek A.
    Bone Marrow Transplant; 2004 May 01; 33(9):931-5. PubMed ID: 15034541
    [Abstract] [Full Text] [Related]

  • 9. [Cytomegalovirus diseases after allogeneic hematopoietic stem cell transplantation (Allo-HSCT) and related risk factors].
    Huang XJ, Xu LP, Ren HY, Zhang YC, Guo NL, Lu DP.
    Zhonghua Yi Xue Za Zhi; 2003 May 10; 83(9):766-9. PubMed ID: 12899755
    [Abstract] [Full Text] [Related]

  • 10. Tetramer monitoring to assess risk factors for recurrent cytomegalovirus reactivation and reconstitution of antiviral immunity post allogeneic hematopoietic stem cell transplantation.
    Borchers S, Luther S, Lips U, Hahn N, Kontsendorn J, Stadler M, Buchholz S, Diedrich H, Eder M, Koehl U, Ganser A, Mischak-Weissinger E.
    Transpl Infect Dis; 2011 Jun 10; 13(3):222-36. PubMed ID: 21585633
    [Abstract] [Full Text] [Related]

  • 11. Valacyclovir for the prevention of cytomegalovirus infection after allogeneic stem cell transplantation: a single institution retrospective cohort analysis.
    Vusirikala M, Wolff SN, Stein RS, Brandt SJ, Morgan DS, Greer JP, Schuening FG, Dummer JS, Goodman SA.
    Bone Marrow Transplant; 2001 Aug 10; 28(3):265-70. PubMed ID: 11535994
    [Abstract] [Full Text] [Related]

  • 12. Monitoring of cytomegalovirus reactivation after allogeneic stem cell transplantation: comparison of an antigenemia assay and quantitative real-time polymerase chain reaction.
    Yakushiji K, Gondo H, Kamezaki K, Shigematsu K, Hayashi S, Kuroiwa M, Taniguchi S, Ohno Y, Takase K, Numata A, Aoki K, Kato K, Nagafuji K, Shimoda K, Okamura T, Kinukawa N, Kasuga N, Sata M, Harada M.
    Bone Marrow Transplant; 2002 Apr 10; 29(7):599-606. PubMed ID: 11979310
    [Abstract] [Full Text] [Related]

  • 13. Human herpes virus 6 plasma DNA positivity after hematopoietic stem cell transplantation in children: an important risk factor for clinical outcome.
    de Pagter PJ, Schuurman R, Visscher H, de Vos M, Bierings M, van Loon AM, Uiterwaal CS, van Baarle D, Sanders EA, Boelens J.
    Biol Blood Marrow Transplant; 2008 Jul 10; 14(7):831-9. PubMed ID: 18541204
    [Abstract] [Full Text] [Related]

  • 14. Cytomegalovirus antigenemia and outcome of patients treated with pre-emptive ganciclovir: retrospective analysis of 241 consecutive patients undergoing allogeneic hematopoietic stem cell transplantation.
    Yanada M, Yamamoto K, Emi N, Naoe T, Suzuki R, Taji H, Iida H, Shimokawa T, Kohno A, Mizuta S, Maruyama F, Wakita A, Kitaori K, Yano K, Hamaguchi M, Hamajima N, Morishima Y, Kodera Y, Sao H, Morishita Y.
    Bone Marrow Transplant; 2003 Oct 10; 32(8):801-7. PubMed ID: 14520425
    [Abstract] [Full Text] [Related]

  • 15. Monitoring cytomegalovirus IE-1 and pp65-specific CD4+ and CD8+ T-cell responses after allogeneic stem cell transplantation may identify patients at risk for recurrent CMV reactivations.
    Gratama JW, Brooimans RA, van der Holt B, Sintnicolaas K, van Doornum G, Niesters HG, Löwenberg B, Cornelissen JJ.
    Cytometry B Clin Cytom; 2008 Jul 10; 74(4):211-20. PubMed ID: 18454493
    [Abstract] [Full Text] [Related]

  • 16. Ex vivo expansion and prophylactic infusion of CMV-pp65 peptide-specific cytotoxic T-lymphocytes following allogeneic hematopoietic stem cell transplantation.
    Micklethwaite K, Hansen A, Foster A, Snape E, Antonenas V, Sartor M, Shaw P, Bradstock K, Gottlieb D.
    Biol Blood Marrow Transplant; 2007 Jun 10; 13(6):707-14. PubMed ID: 17531781
    [Abstract] [Full Text] [Related]

  • 17. Cytomegalovirus infection in children undergoing hematopoietic stem cell transplantation in Chile.
    Paris C, Kopp K, King A, Santolaya ME, Zepeda AJ, Palma J.
    Pediatr Blood Cancer; 2009 Sep 10; 53(3):453-8. PubMed ID: 19418548
    [Abstract] [Full Text] [Related]

  • 18. Cytomegalovirus infection and disease after allogeneic hematopoietic stem cell transplantation: experience in a center with a high seroprevalence of both CMV and hepatitis B virus.
    Liu YC, Lu PL, Hsiao HH, Chang CS, Liu TC, Yang WC, Lin SF.
    Ann Hematol; 2012 Apr 10; 91(4):587-95. PubMed ID: 21997849
    [Abstract] [Full Text] [Related]

  • 19. Ganciclovir prophylaxis for cytomegalovirus infection in pediatric allogeneic bone marrow transplant recipients.
    Canpolat C, Culbert S, Gardner M, Whimbey E, Tarrand J, Chan KW.
    Bone Marrow Transplant; 1996 Apr 10; 17(4):589-93. PubMed ID: 8722360
    [Abstract] [Full Text] [Related]

  • 20. Fludarabine-based reduced intensity conditioning transplants have a higher incidence of cytomegalovirus reactivation compared with myeloablative transplants.
    George B, Kerridge I, Gilroy N, Huang G, Hertzberg M, Gottlieb D, Bradstock K.
    Bone Marrow Transplant; 2010 May 10; 45(5):849-55. PubMed ID: 19915635
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 57.